Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
122M
-
Number of holders
-
79
-
Total 13F shares, excl. options
-
51.6M
-
Shares change
-
-527K
-
Total reported value, excl. options
-
$178M
-
Value change
-
-$5.42K
-
Put/Call ratio
-
0.27
-
Number of buys
-
36
-
Number of sells
-
-29
-
Price
-
$3.45
Significant Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q1 2024
85 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q1 2024.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.6M shares
of 122M outstanding shares and own 42.42% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (11.4M shares), Frazier Life Sciences Management, L.P. (7.38M shares), Rubric Capital Management LP (5.56M shares), VIKING GLOBAL INVESTORS LP (4.4M shares), VR Adviser, LLC (3.42M shares), Opaleye Management Inc. (2.65M shares), BlackRock Inc. (2.38M shares), VANGUARD GROUP INC (2.3M shares), Logos Global Management LP (2.2M shares), and MPM BIOIMPACT LLC (1.34M shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.